Stock Scorecard
Stock Summary for XBiotech Inc (XBIT) - $2.57 as of 10/24/2025 9:04:01 PM EST
Total Score
13 out of 30
Safety Score
26 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for XBIT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for XBIT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for XBIT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for XBIT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for XBIT (26 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 10 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 3 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for XBIT
Financial Details for XBIT
Company Overview |
|
|---|---|
| Ticker | XBIT |
| Company Name | XBiotech Inc |
| Country | USA |
| Description | XBiotech Inc. is a transformative biopharmaceutical company based in Austin, Texas, specializing in the development of True Human monoclonal antibodies aimed at treating a range of diseases. Leveraging advanced technology to utilize human immune cells, the company seeks to create innovative and safer therapeutic options. With a diverse and promising pipeline, XBiotech is strategically positioned as a frontrunner in the biotherapeutics arena, committed to enhancing patient care and addressing significant unmet medical needs across multiple therapeutic areas. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/6/2025 |
Stock Price History |
|
| Last Day Price | 2.57 |
| Price 4 Years Ago | 11.13 |
| Last Day Price Updated | 10/24/2025 9:04:01 PM EST |
| Last Day Volume | 70,897 |
| Average Daily Volume | 62,981 |
| 52-Week High | 8.32 |
| 52-Week Low | 2.35 |
| Last Price to 52 Week Low | 9.36% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.95 |
| Sector PE | 41.12 |
| 5-Year Average PE | -11.21 |
| Free Cash Flow Ratio | 0.51 |
| Industry Free Cash Flow Ratio | 14.54 |
| Sector Free Cash Flow Ratio | 31.25 |
| Current Ratio Most Recent Quarter | 40.16 |
| Total Cash Per Share | 5.02 |
| Book Value Per Share Most Recent Quarter | 5.68 |
| Price to Book Ratio | 0.47 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.29 |
| Price to Sales Ratio Twelve Trailing Months | 12.23 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.95 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.43 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 30,487,700 |
| Market Capitalization | 78,353,389 |
| Institutional Ownership | 11.35% |
Dividends |
|
| Ex-Dividend Date | 7/15/2021 |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 2.4700 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 1 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -56.90% |
| Reported EPS 12 Trailing Months | -0.91 |
| Reported EPS Past Year | -0.42 |
| Reported EPS Prior Year | -1.26 |
| Net Income Twelve Trailing Months | -28,163,000 |
| Net Income Past Year | -38,531,000 |
| Net Income Prior Year | -24,557,000 |
| Quarterly Revenue Growth YOY | -93.30% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 152,938,000 |
| Total Cash Past Year | 172,677,000 |
| Total Cash Prior Year | 200,023,000 |
| Net Cash Position Most Recent Quarter | 142,938,000 |
| Net Cash Position Past Year | 172,677,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 10,000,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.95 |
| Total Stockholder Equity Past Year | 182,268,000 |
| Total Stockholder Equity Prior Year | 218,846,000 |
| Total Stockholder Equity Most Recent Quarter | 173,064,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -25,661,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.84 |
| Free Cash Flow Past Year | -32,267,000 |
| Free Cash Flow Prior Year | -19,087,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.08 |
| MACD Signal | -0.09 |
| 20-Day Bollinger Lower Band | 2.37 |
| 20-Day Bollinger Middle Band | 2.82 |
| 20-Day Bollinger Upper Band | 3.27 |
| Beta | 0.84 |
| RSI | 39.38 |
| 50-Day SMA | 3.60 |
| 150-Day SMA | 4.75 |
| 200-Day SMA | 5.20 |
System |
|
| Modified | 10/23/2025 12:57:36 PM EST |